Navigation Links
Swedish Biotech Licenses HIV Drug to China for Development

The Swedish biotechnology company Medivir announced yesterday that it has licensed its experimental non-nucleoside// reverse transcriptase inhibitor (NNRTI), code-named MIV-160, to the Chinese company Guangdong Lantai Viewland Pharmaceutical for the China region. Medivir will retain the worldwide rights to the product.

Guangdong Lantai Viewland Pharmaceutical will potentially develop MIV-160 for three different products; an oral treatment regime, a vaginal microbicide and coating of condoms. It is the first antiretroviral product to be investigated as an additive agent to condom lubrication.

Professor Bo Oberg, head of the HIV franchise at Medivir, told aidsmap: 'This should enhance the safety of condoms and will at least save a few infections.'

MIV-160 is also an attractive microbicide product, he said, because it can inhibit HIV at very low concentrations – several thousand times lower than products currently being investigated in phase III trials in Africa. A second Medivir NNRTI – MIV-150 – is being investigated in combination with the microbicide Carraguard in a phase I study.

Medivir says that MIV-160, still in pre-clinical development, has shown good activity against NNRTI-resistant virus.

It is the first time that a Chinese company has won the global rights to develop an HIV product. Prof. Oberg said that Medivir will retain the right to commercialise or license any developments that result from the partnership for the rest of the world.

Medivir is also involved in two other development partnerships, with Tibotec for an HIV protease inhibitor and a nucleoside analogue, and with Bristol Myers Squibb for the NNRTI MIV-170.

Source-Bio-Bio Technology

Page: 1

Related medicine news :

1. Sick Swedish seagull was drunk, not affected by bird flu
2. GE Healthcare to Acquire Swedish Medical Company
3. Biotechnology industry expected to grow into a three billion dollar industry by 2002
4. Biotechnology on the lead
5. Panacea Biotech To Market Anthrax Vaccine
6. Commercialization of Biotech Discoveries, An Encouragement For Researchers
7. Biotech drug causing anemia-EPREX
8. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
9. Biologicals Transfer Proposal between US and Indian Biotechnology
10. Vical Biotech and NIH jointly develops HIV vaccine
11. Biotechnology Initiatives Planned In Hyderabad
Post Your Comments:

(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: